Alexandros Alexandropoulos: Some thoughts on Multiple Melanoma clinical trials practice and restrictions
Alexandros Alexandropoulos, Hematologist at Laiko General Hospital, shared a post on X:
“Some thoughts on Multiple Melanoma clinical trials practice and restrictions:
1. Don’t put an upper age limit. Many old patients are underserved and understudied because of that.
2. Time to include PCL patients by default. Modern combos give a modest benefit but we can’t exclusively rely on indirect evidence or retrospective real-world data.
3. Stop using the words “manageable” or “modest” to describe AE’s. Stick to the standardized grading system and include QoL assessments for these AE’s, they are not all equally miserable.
4. Yes, MRD does correlate with PFS, but is more easily lost than losing CR. Exploratory phase 1-2 trials will probably benefit from the recent FDA decision the most (and provide data faster), but I would like to see phase 3 trials stick to PFS and TTNT.”
Source: Alexandros Alexandropoulos/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023